Evan Seigerman’s Buy Rating on Regeneron: Overcoming Challenges with a Promising Pipeline and Undervalued Assets

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at $865.00.

Evan Seigerman has given his Buy rating due to a combination of factors influencing Regeneron’s current and future performance. Despite facing challenges in the first quarter of 2025, such as increased competition and inventory issues affecting Eylea, Seigerman sees potential in the company’s pipeline and its ability to convert research and development spending into growth.
The analyst acknowledges the impact of the Complete Response Letter (CRL) for Eylea HD, which could dampen sales if not resolved, but remains optimistic about Regeneron’s prospects. He highlights the company’s oncology franchise and early-stage pipeline as areas of strength, suggesting that the market is undervaluing these assets at the current share price. Seigerman’s confidence in Regeneron’s long-term success in the biotech sector underpins his Buy rating.

In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $800.00 price target.